ARIAD pipeline:
robust, focused, exciting in its potential.

Our pipeline currently contains three promising compounds: ridaforolimus (formerly called deforolimus), AP24534 and AP26113. Each was discovered by our own people. Each targets a proven pathway to disrupting cancer growth. Each is being explored in multiple indications, chosen for the highest likelihood of success and potential for patient impact.